Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 69.00
+4.25 (6.56%)
Mar 6, 2026, 4:08 PM HKT
Shanghai Henlius Biotech Market Cap
Shanghai Henlius Biotech has a market cap or net worth of 37.5 billion as of March 6, 2026. Its market cap has increased by 230.14% in one year.
Market Cap
37.50B
Enterprise Value
40.46B
Revenue
6.35B
Ranking
n/a
PE Ratio
41.52
Stock Price
69.00
Market Cap Chart
Since September 25, 2019, Shanghai Henlius Biotech's market cap has increased from 26.66B to 37.50B, an increase of 40.66%. That is a compound annual growth rate of 5.43%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 37.50B | 20.95% |
| Dec 31, 2025 | 31.01B | 140.72% |
| Dec 31, 2024 | 12.88B | 70.50% |
| Dec 29, 2023 | 7.55B | 8.59% |
| Dec 30, 2022 | 6.96B | -41.95% |
| Dec 31, 2021 | 11.98B | -53.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Sep 25, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| RemeGen | 52.91B |
| 3SBio | 49.10B |
| Biocytogen Pharmaceuticals (Beijing) | 31.54B |
| Shanghai Junshi Biosciences | 30.61B |
| Duality Biotherapeutics | 25.69B |
| Genscript Biotech | 23.70B |
| TransThera Sciences (Nanjing) | 23.44B |
| PegBio | 23.43B |